Medical devices often penetrate the boundaries of the body, making them vulnerable to bacterial infection. British scientists have enlisted bacteriophages, or viruses that specifically target and kill bacteria, in their effort to reduce medical device-derived infections. Specifically, the researchers used them against Proteus mirabilis, a bacteria that commonly encrusts and blocks urinary catheters. This can lead to kidney infection or even septicemia, which can be deadly. Bacterial infection in an age when the number of bacteria resistant to antibiotic treatment is growing rapidly can prove problematic, particularly in a hospital setting that is rife with virulent microorganisms. "Our work provides good initial evidence that bacteriophage can treat infections caused by Proteus mirabilis and prevent catheter blockage," said Dr. Brian Jones, the head of research development at Queen Victoria Hospital in East Grinstead, West Sussex, in a statement. "This could lead to new ways of managing patients fitted with urinary catheters, providing much benefit to a large number of patients, and also contribute to reducing antibiotic use and tackling resistance. We are still at a very early stage in this work, and have a long way to go before we can be sure this will lead to an effective way to control these infections, but bacteriophage have been used extensively in other countries for decades, and the challenge of antibiotic resistance makes it important to look at using these promising alternatives to antibiotics. We think an important issue will be in developing ways to deliver bacteriophage as needed, which is a key aim of our ongoing work." Release
@FierceMedDev: Anne Wojcicki, Elizabeth Holmes, Andrew Conrad make 2016's most influential people in biopharma list. FierceBiotech feature | Follow @FierceMedDev
@VarunSaxena2: FDA panel set to review its first bioresorbable stent, Abbott's Absorb. Report | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: Hospitals join drug price-fighting battalion with plans to crack down on spending. Report | Follow @EmilyWFierce
> Baxter ($BAX) has started enrollment for a U.S. clinical trial of its Vivia home hemodialysis system that it developed in conjunction with DEKA Research & Development Corporation. More
> Anesthesiologists may have killed off Johnson & Johnson's ($JNJ) Sedasys Automated Sedation System; the conglomerate has halted sales of the system, which was intended to offer surgical cost savings but thereby could have encroached upon anesthesiologist turf--and income. WSJ story
> Sight Sciences has raised a $7 million Series B to help it scale manufacturing, develop manufacturing and support clinical trials for its minimally invasive surgical and evaporative dry eye products. More
Biotech News
@FierceBiotech: Tiny Celator surges on promising cancer data and preps an FDA submission. Article | Follow @FierceBiotech
@JohnCFierce: Gee, Lilly drops function as a co-primary endpoint for sola. Anyone a wee bit nervous? Release | Follow @JohnCFierce
> Lilly moves the goal line in its make-or-break Alzheimer's trial. Report
> Roche's new PD-L1 bladder cancer drug could be on the market by September. More
> Roche bets up to $1B on Blueprint's precision medicine platform. Article
Pharma News
@FiercePharma: ICYMI yesterday: Patent challenger Bass wins another review bid, this time on Acorda's Ampyra. Story | Follow @FiercePharma
@CarlyHFierce: Ex-Sanofi, Schering CEOs were on a short list to replace Valeant chief Pearson: WSJ. More | Follow @CarlyHFierce
> Zydelig 'dead in the water' after trial deaths force Gilead to stop frontline studies. Report
> Specialty-drug spending set for double-digit leaps over the next 3 years: Express Scripts. More
Drug Delivery News
> 'Smart' diabetes patch uses real beta cells to react to blood sugar and release insulin. Story
> Artificial liposomes bypass immune system to release cardio drugs. More
> Harvard team develops blood-brain-barrier-on-a-chip to study drug delivery. Report
> EyeGate adds drug-delivering hydrogel to its pipeline with acquisition of Jade Therapeutics. Story
> Eli Lilly reports promising early-stage results for its fast-acting insulin formulation. Article
Pharma Manufacturing News
> Lupin plant in Goa smacked by the FDA. Report
> China's FDA urged to get track and trace system in place. Item
> Iran drugmaker agrees to build plant in Azerbaijan. Report
> Pfizer, Abbott cough syrups banned by Indian regulator in fight over opiates. Article
> Amgen strikes deal with Patheon for 'flexible manufacturing capacity.' Story
Pharma Asia News
> India still reviewing prospects for mandated cuts in drug prices. Item
> GSK's Witty hears the rhythm in China's drumbeat for lower prices. More
> India lifts alert on Roche's Avastin use for eye injection. Story
> SK Bio's epilepsy drug gets U.S. FDA exemption from PhIII efficacy step. News
> India's Dr. Reddy's works with Turkey's TR-Pharm on biosimilars. Article